Product News

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that Darzalex ®(daratumumab) in combination with lenalidomide and dexamethasone (DRd)

IRELAND’S HSE APPROVES LILLY’S ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF PEOPLE WITH HR+, HER2- EARLY BREAST

AbbVie has announced that the Irish health authorities have approved reimbursement of PRODUODOPA® (foslevodopa/foscarbidopa) for the treatment of advanced levodopa-responsive

End-of-trial data show 79.7% efficacy in participants aged 50 years and over during long-term follow-up, six to 11 years after

Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide

Following a 30-year joint venture, Sandoz, the world’s largest generics and biosimilars company, has acquired full ownership of Rowex. Rowex

Dostarlimab plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the

Astellas Pharma recently announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for enfortumab vedotin in